Boardroom Alpha
Meeting calendar
STTK · Annual meeting · Thursday, May 28, 2026

Shattuck Labs Inc

7 nominees · 5 ballot items.

Election of three Class III directors; ratification of KPMG as auditor; advisory approval of executive compensation (say-on-pay); advisory vote on frequency of say-on-pay (one, two, or three years); and approval of amendment and restatement of the 2020 Equity Incentive Plan.

Market cap
$577M
1Y TSR
+687.1%
Board grade
C
Record date
Apr 2, 2026
Filing
DEF 14A
Meeting concluded · May 28, 2026

Follow how the vote landed and what changed on Shattuck Labs Inc’s board — director track records, governance grades, and ongoing monitoring — on the Boardroom Alpha platform.

Proposals

On the ballot5

  1. 1

    Election of Directors

    ManagementBoard: FOR

    Elect three Class III director nominees (Taylor Schreiber, Helen M. Boudreau, Clay Siegall) to serve until the 2029 Annual Meeting.

  2. 2

    Ratification of Independent Auditor Selection

    ManagementBoard: FOR

    Ratify the Audit Committee’s selection of KPMG LLP as the Company’s independent registered public accounting firm for the year ending December 31, 2026.

  3. 3

    Advisory Vote on Executive Compensation (Say-on-Pay

    ManagementBoard: FOR

    Non-binding, advisory vote to approve the compensation of the Company’s named executive officers.

    More detail

    Proposal 3 requests a non-binding advisory approval of the compensation paid to the company’s named executive officers (NEOs) as disclosed in the proxy. Management seeks shareholder endorsement of its pay program to validate its executive compensation philosophy, which emphasizes alignment with long-term shareholder value through base salary, performance-based annual bonuses tied to corporate and individual goals, and multi-year equity awards. The Compensation Committee uses peer benchmarking and engaged Aon as an independent consultant, and the Board argues these processes produce appropriate pay levels and incentive design. Because the vote is advisory, the outcome does not alter pay arrangements directly but is intended to provide feedback that the Compensation Committee and Board will consider when setting future compensation. Context: Shattuck is a smaller reporting company with significant equity-based compensation; management emphasizes retention and performance-linked awards, occasional performance-based vesting conditions, and existing clawback/recovery and insider trading policies to mitigate risk. If voted against by significant shareholders, the Board may engage with investors and could modify future pay practices. The Board recommends a “FOR” vote, asserting that the current program supports the company’s strategy and aligns executive and shareholder interests.

  4. 4

    Advisory Vote on Frequency of Future Advisory Votes on Executive Compensation

    ManagementBoard: FOR

    Non-binding, advisory vote where stockholders choose whether future say-on-pay votes should occur every one, two, or three years; Board recommends one year.

    More detail

    Proposal 4 asks shareholders, in a non-binding advisory vote, to select the frequency (1, 2, or 3 years) for future say-on-pay votes. Management recommends annual votes (one year) to maintain regular shareholder engagement and oversight of executive pay. The Board stresses that the vote is advisory and will consider the option receiving the most votes. Context includes regulatory requirements to hold frequency votes at least every six years and the company’s decision to hold say-on-pay annually unless shareholders indicate otherwise. The Board’s rationale is that annual votes better enable responsiveness to evolving compensation practices and performance alignment; however, a plurality choice could still guide policy without being binding.

  5. 5

    Amendment and Restatement of the Company’s 2020 Equity Incentive Plan

    ManagementBoard: FOR

    Approve an amendment and restatement of the 2020 Equity Incentive Plan to: (1) change the basis of the automatic annual share increase to include shares underlying unexercised pre-funded warrants and shares underlying outstanding preferred stock on an as-converted basis; (2) add 1,691,082 additional shares; and (3) extend the outside date for ISOs to March 23, 2036.

    More detail

    Proposal 5 requests shareholder approval to amend and restate the company’s 2020 Equity Incentive Plan to account for a shift in capital structure after recent financings that increased pre-funded warrants and decreased common stock proportion. The amendment seeks three targeted changes: broaden the ‘evergreen’ automatic annual increase calculation to include shares underlying pre-funded warrants and preferred stock (as-converted) so that the 4% annual increase better reflects total outstanding capital; add a one-time increase of 1,691,082 shares to capture the amount that would have been added had the amended calculation been in effect earlier; and extend the date through which ISOs may be granted to March 23, 2036. Management argues these changes preserve the plan’s original intent to maintain sufficient share reserves for recruiting and retention and to prevent dilution-related shortages. The Board recommends a “FOR” vote, noting that the plan’s administration, share limits, and governance controls remain otherwise unchanged. The proposal has compensation governance implications: it increases available equity for employee incentives and could affect dilution and shareholder returns; absent approval, future equity grant capacity may be constrained, potentially harming retention. The Board justifies the change by reference to the company’s recent financing activity and the aim to align the plan mechanics with actual capital structure.

Director elections

Nominees on the ballot7

Independent
Tenure on this board
0.9 yrs
Also a director at
Artiva Biotherapeutics Inc (ARTV)
Independent
Tenure on this board
6.0 yrs
Also a director at
Rallybio Corp (RLYB)
Independent
Tenure on this board
9.7 yrs
Also a director at
Instil Bio Inc (TIL)
Ownership

Top institutional holders10

Latest 13F quarter
1T. Rowe Price Investment Management, Inc.12.9%9,865,558$63M
2ORBIMED ADVISORS LLCActivist8.2%6,306,127$41M
3Redmile Group, LLC7.2%5,539,724$36M
4Prosight Management, LP6.5%5,004,439$32M
5ADAGE CAPITAL PARTNERS GP, L.L.C.6.1%4,644,957$30M
6NEXTBio Capital Management LP4.1%3,149,907$20M
7VANGUARD CAPITAL MANAGEMENT LLC3.0%2,277,176$15M
8PRICE T ROWE ASSOCIATES INC /MD/2.3%1,782,788$11M
9CLARK ESTATES INC/NY1.9%1,475,648$9M
10PINNACLE ASSOCIATES LTD1.8%1,368,223$9M
Filings

Recent key filings

Periodic reports
Definitive proxies
Reference

Frequently asked questions

When is the Shattuck Labs Inc 2026 annual meeting?
Shattuck Labs Inc (STTK) holds its 2026 annual shareholder meeting on Thursday, May 28, 2026.
What is the record date for the Shattuck Labs Inc 2026 meeting?
The record date for the Shattuck Labs Inc 2026 meeting is Thursday, April 2, 2026. Shareholders of record on or before that date are eligible to vote.
Who are the director nominees for Shattuck Labs Inc's 2026 meeting?
The board is presenting 7 director nominees at the Shattuck Labs Inc 2026 meeting, listed with their independence status and background.
What proposals will shareholders vote on at the Shattuck Labs Inc 2026 meeting?
Shareholders will vote on 5 proposals at the Shattuck Labs Inc 2026 meeting, each tagged with who proposed it and the board's recommendation.
Disclaimer

The opinions and information contained herein have been obtained or derived from sources believed to be reliable, but Boardroom Alpha cannot guarantee its accuracy and completeness, and that of the opinions based thereon.

This report contains opinions and is provided for informational purposes only – it does not constitute investment, legal or tax advice. You should not rely solely upon the research herein for purposes of transacting securities or other investments, and you are encouraged to conduct your own research and due diligence, and to seek the advice of a qualified securities professional before you make any investment.

None of the information contained in this report constitutes, or is intended to constitute a recommendation by Boardroom Alpha of any particular security or trading strategy or a determination by Boardroom Alpha that any security or trading strategy is suitable for any specific person. To the extent any of the information contained herein may be deemed to be investment advice, such information is impersonal and not tailored to the investment needs of any specific person.

No representation or warranty, expressed or implied, is made on behalf of Boardroom Alpha as to the accuracy or completeness of the information contained herein. Boardroom Alpha does not accept any liability for any direct, indirect or consequential loss or damage suffered by any person as a result of relying on all or any part of this research and any liability is expressly disclaimed.

Full disclaimer